Select Page

Edmonton, May 28-30, 2023

Due to the numerous requests from LPs. Micro and Craft growers along with some of the largest cannabis retail stores in the nation, Grow Up has decided to bring our award winning show to Alberta. We will be hosting our 7th Conference and Expo at the Edmonton Convention Centre in beautiful downtown Edmonton.

US Doctors Could Prescribe MDMA in 2024

Media Partners, Psychedelic News Wire

This post is presented by our media partner Psychedelic News Wire
View the original article here.

MDMA is a stimulant drug that causes hallucinations. Researchers have found that the drug, which is also known as ecstasy or molly, may be useful in the treatment of  a range of mental health conditions, including anxiety.

A recently conducted medical trial also found that the drug, which is popular in rave culture, could effectively treat post-traumatic stress disorder. Post-traumatic stress disorder is a mental health condition that’s usually triggered when an individual witnesses or experiences a traumatic event. Symptoms may include nightmares, flashbacks and severe anxiety, among other things.

The trial was carried out by Multidisciplinary Association for Psychedelic Studies (MAPS), which is a not-for-profit organization that’s focused on raising awareness of psychedelic substances. For their study, the researchers recruited 90 participants suffering from severe post-traumatic disorder. Each of these patients received either a placebo or a 120 mg or 80 mg dose of MDMA. Once the treatment was administered, the patients were given headphones to listen to music and eye masks to wear while they sat with the researchers to observe how they reacted.

Once two hours had elapsed, the researchers administered an additional booster dose of between 40 to 60 mg, after which the patients went for 90-minute therapy sessions to discuss their experiences.

The trial’s results show that almost 90% of the participants experienced substantial improvements in their symptoms following their third therapy session. Another 67% also noted that there was so much progress that they no longer experienced symptoms that would warrant a post-traumatic stress-disorder diagnosis.

The researchers also observed a separate control group that did not receive MDMA but did receive counseling. They found that of the total number of participants in that group, one-third were cured of their symptoms of PTSD over the same period of time.

In their report, the researchers revealed that they planned to begin the process for obtaining drug approval from the FDA, noting that they planned to file a New Drug Application in the third quarter of 2023. The Food and Drug Administration may take roughly six months to approve or reject the application.

If the drug is approved by 2024, we could see MDMA being administered to millions of adults who suffer from post-traumatic stress disorder. At the moment, however, MDMA is classified as a Schedule I drug under the Controlled Substances Act. Drugs under this classification are not accepted for use in treatment in the United States and are believed to have a high potential for abuse.

If these drugs hit the market, psychedelic startups such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are likely to attract a lot more investor interest given the upward potential that approved drugs present.

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

This post was originally published by our media partner here.